Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio)

Folia Histochemica et Cytobiologica

Volumn 48, Issue 1, 2010, Pages 19-25

  Słodkowska, Janina ^a   Filas, Violetta ^b   Buszkiewicz, Elzbieta ^b   Trzeciak, Paweł ^b   Wojciechowski, Michał ^c   Koktysz, Robert ^a   Staniszewski, Wojciech ^c   Breborowicz, Jan ^b   Rojo, Marcial Garcia ^d  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b GREATER POLAND CANCER CENTRE   (Poland)

^c Precoptic Co   (Poland)

^d HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

ACIS, APERIO; Automated quantisation; ER PR expression; Her 2 neu scoring; Hormonal receptors; Manual scoring

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; RECEPTOR ANTIBODY;

ACCURACY; ARTICLE; AUTOMATION; BREAST CARCINOMA; CANCER PATIENT; DEVICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; MICROSCOPY; PATHOLOGIST; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; SCORING SYSTEM; STANDARDIZATION;

ACIS;

EID: 77954369900     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-010-0015-1     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. World Health Organisation Classification of tumours: Pathology and genetics of tumours of the breast and female genital organs. Tavassoli FA&Devilee P. IARCPress, Lyon, 2003:13.
3. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
4. Umemura S, Kurosumi M, Moriya T et al. Immunohistochemical Evaluation for Hormone Receptors in Breast Cancer: A Practically Useful Evaluation System and Handling Protocol. Breast Cancer. 2006;13: 232-235.
5. Kurosumi M. Immunohistochemical Assessment of Hormone Receptor Status Using a New Scoring System (J-Score) in Breast Cancer. Breast Cancer. 2007;14:189-193.
6. Tawfik OW, Kimler BF, Davis M et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258-267.
7. Wang S, Saboorian MH, Frenkel EP et al. Assessment of HER-2/neu Status in Breast Cancer. Automated Cellular Imaging System (ACIS)-Assisted Quantitation of Immunohistochemical Assay Achieves High Accuracy in Comparison With Fluorescence In Situ Hybridization Assay as the Standard. Am J Clin Pathol. 2001;116:495-503.
8. Peces C, Garcia-Rojo M, Sacristan J, Gallardo AJ, Rodriguez A. Serendipia: Castilla-La Mancha telepathology network. Diagn Pathol. 2008;3(suppl.1): S5.
9. Gilbertson J, Yagi Y. Histology, imaging and new diagnostic work-flow in pathology. Diagn Pathol. 2008;3 (suppl.1):S14.
10. Miller K. Immunocytochemical Techniques. In: Bancroft JD. Gamble M.: Theory and Practice of Histological Techniques. Churchill Livingstone; 2002, pp. 421-464.
11. Briner P, Oberhuber G, Stani J et al. Evaluation of the United Sates Food and Drug Administration - approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
12. Bloom K, Harrington D. Enhanced Accuracy and Reliability of Her-2/neu Immunohistochemical Scoring Using Digital Micoroscopy. Am J Clin Pathol. 2004;121:620-630.
13. Fornier M, Risio M, Poznak C, Seidman A. Her-2 Testing and Correlation with Efficacy of Transtuzumab Therapy. Oncology. 2002;16:1340-1358.
14. Goldstein NS, Hewitt SM, Taylor CR et al., and Members of Ad-Hoc Committee on Immunohistochemistry. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15:124-133.
15. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The Effects of Fixation, Processing and Evaluation Criteria on Immunohistochemical detection of Hormone receptors in Breast Cancer. Breast Cancer. 2007;14:182-188.
16. Sharangpani GM, Joshi AS, Porter K et al. Semi-automated imaging system to quantitate estrogren and progesterone receptor immunoreactivity in human breast cancer. J Microscopy. 2007;226:244-255.
17. Press M, Spaulding B, Groshen S et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroid. 2002;67:799-813.
18. Fischer ER, Anderson S, Dean S et al.: Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005;103:164-173.
19. Rocha R, Nunes C, Rocha G et al.: Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. Pathol Res Pract. 2008;204: 655-662.
20. Rexhepaj E, Brennan DJ, Holloway P et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 2008;10(5):R89.
21. Gokhale S, Rosen D, Sneige N et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007;15:451-455.
22. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol. 2004;8:23-27.